glp 1 agonist in heart failure GLP-1RAs reduce cardiovascular deaths patients with CKM comorbidity | Duke Clinical Research Institute posted on the topic GLP-1 Agonists in Cardiovascular Diseases:

Take 1-4 doses per day

doi: 10.1016/j.ijcard.2020.06.011 105 CahnAWiviottSDMosenzonOMurphySAGoodrichELYanuvIet al

These alternatives typically show lower efficacy than GLP-1s but provide meaningful benefits at reduced cost

2A), warranting clinical studies

GLP-1 RA Head-to-Head Trials In summary, these head-to-head clinical trials between GLP-1RA and DPP-4 inhibitors showed that the difference between the drugs lies in the ability of the GLP-1RA to consistently improve glycemic control and decrease weight ( Switch Trials A small number of clinical trials have evaluated switching patients from a DPP-4 inhibitor (sitagliptin) to a GLP-1RA

These medications can complement each other by addressing different aspects of hunger and satiety, but the potential strain on the heart and the increase in side effects require professional guidance